Home > Boards > Canadian > Cannabis > TILRAY, INC (TLRY)

3 Things to Know About Tilray and Anheuser-Busch's

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
FUNMAN Member Profile
Member Level 
Followed By 73
Posts 18,440
Boards Moderated 13
Alias Born 08/03/10
160x600 placeholder
Tilray, Inc. Completes Merger With Privateer Holdings, Inc. Business Wire - 12/13/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/12/2019 5:24:47 PM
Tilray® erhält zusätzliche GMP-Zertifizierung für den EU Campus und internationale Exporterlaubnis für medizinische Cann... Business Wire - 12/11/2019 1:00:00 PM
Tilray® Receives Additional GMP Certification at EU Campus Allowing for International Export of Finished Medical Cannabis Pr... Business Wire - 12/11/2019 8:00:00 AM
Tilray® Expands Global Leadership Team With New Manitoba Harvest President Business Wire - 12/3/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 5:13:30 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 11/13/2019 8:03:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/13/2019 6:01:09 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/12/2019 5:21:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:11:58 PM
Tilray, Inc. Reports Third Quarter 2019 Financial Results Business Wire - 11/12/2019 4:05:00 PM
Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a) Edgar (US Regulatory) - 11/8/2019 5:12:31 PM
IntelGenx Reports Third Quarter 2019 Financial Results GlobeNewswire Inc. - 11/7/2019 4:01:00 PM
Tilray to Report Third Quarter 2019 Financial Results on November 12, 2019 Business Wire - 10/29/2019 8:00:00 AM
Tilray® Supports New Clinical Trial Evaluating the Efficacy of Medical Cannabis in Disorders Caused by Breast Cancer Treatme... Business Wire - 10/24/2019 8:00:00 AM
High Park™ dévoile un portefeuille complet de marques et produits pour la prochaine phase de développement de cannabis à... Business Wire - 10/16/2019 9:35:00 AM
High Park™ Unveils Comprehensive Portfolio of New Brands and Products for the Next Phase of Adult-Use Cannabis in Canada Business Wire - 10/16/2019 9:00:00 AM
Securities Registration: Business Combination (s-4) Edgar (US Regulatory) - 10/11/2019 6:01:23 AM
Hemp Set to Overtake Tobacco in Kentucky Amid Boom for Growers, Suppliers NetworkNewsWire - 9/11/2019 8:45:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/11/2019 6:33:15 AM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 9/10/2019 5:24:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 5:24:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 6:11:24 AM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 9/10/2019 6:09:29 AM
Tilray, Inc. & Privateer Holdings, Inc. Sign Definitive Agreement to Extend Lock-up & Provide for Orderly Distribution of 75 ... Business Wire - 9/9/2019 8:00:00 AM
FUNMAN Member Level  Monday, 10/14/19 08:55:54 PM
Re: olsen124 post# 3090
Post # of 3297 
3 Things to Know About Tilray and Anheuser-Busch's Cannabis Beverage JV
By: Stephen L Kanaval
Monday, 14 October 2019 13:59 (EST)

https://www.equities.com/news/3-things-to-know-about-tilray-and-anheuser-busch-cannabis-beverage-jv

I wonder how this will effect Tilray's and BUD's financials or is this just a separate stand alone company?

Announced back in December 2018, the joint venture between Tilray and Anheuser-Busch InBev now has a name: Fluent Beverage Company.


What They are Working On

Tilray, participating through its High Park subsidiary, and AB InBEv, participating through its subsidiary Labatt Breweries, are developing a non-alcoholic, CBD-infused beverage available for sale by the end of the year, according to the press release December 2019. Of course, this launch estimate will be based on approvals from Health Canada and provincial regulators. The joint venture has been researching both THC and CBD beverages “leveraging their collective expertise,” but it appears as if the CBD beverage line will be the first to hit shelves.

A THC beverage will probably follow soon after the CBD beverage launch.

Something else to note, this deal is only limited to the Canadian market.

Who is Leading the Fluent JV
Jorn Socquet is the Fluent JV CEO and he has been with AB InBev for 14 years in various capacities. Socquet has gathered researchers and experts from both Labatt and High Park to work on the cannabis beverage options.

"Leading Fluent in my return to Canada has been very exciting. To be Fluent means to have mastery of a subject or skill. We have assembled a team with best-in-class expertise from the beverage and cannabis industries and together we are reaching higher for our consumers, with a shared commitment to setting the standard for product quality and responsible marketing," Socquet said in the company statement.

What is the size of the market

Each company has $50 million invested in the JV. According to Molson Coors during their announcement on a deal with Hexo, the company believes this cannabis beverage market is worth an estimated $3 billion.

Tilray and AB InBev will not have the market to themselves for long. Constellation Brands and Canopy Growth along with Hexo and Molson Coors – their JV is called Truss - will be following shortly after along with a whole host of smaller brands.

Of course, AB InBev has distribution channels that are extremely appealing, so putting the drink in front of interested consumers will not be a problem, it is just understanding what consumers’ taste will be. This is a brand-new segment in the beverage aisle and really this is anybody’s game.

Lastly, the risks of this venture producing little are certainly there. CBD beverages already exist and taste-wise, well, they have been hit or miss. Furthermore, Health Canada's slow-moving approval process has hampered the entire cannabis sector and this December launch could easily be moved into Q1 2020 in a flash.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist